Sleep Quality Among Inpatients With Acute Myeloid Leukemia.

82 Background: Anecdotally, sleep is thought to be a significant problem for inpatients receiving treatment for acute myeloid leukemia (AML), butsleep disturbances in this setting are not well-characterized. We aimed to assess the feasibility of measuring sleep in AML patients using a wearable actigraphy device. Methods: Using the Actigraph GT3X “watch,”we assessed the total sleep time, sleep onset latency, wake after sleep onset, number of awakenings after sleep onset, and sleep efficiency for inpatients with AML receiving induction chemotherapy during their hospitalization. We also assessed patient self-reported sleep quality using the Pittsburgh Sleep Questionnaire Index (PSQI). Results: Of the thirteen patients enrolled in the study, 11 completed actigraphy and PSQI assessments. Two patients who were transferred to the ICU were excluded from this analysis. Data collection was feasible; patients wore the Actigraph device for a mean (SD) of 120 (58) hours. Subjects’ mean age was 55.9 (15.7) years. Mean ...